The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant (Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.1-3
STANDARD TREATMENT — Pharmacologic options for prevention of motion sickness are limited. Over-the-counter...
- Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
- In Brief: An Expanded Indication for Teplizumab (Tzield)
- In Brief: Widaplik — Another Three-Drug Combination for Hypertension
- In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis
- In Brief: Apixaban vs Rivaroxaban for Acute VTE
- Comparison Chart: Drugs for Motion Sickness (online only)
RELEASE
Differin Epiduo gel (Galderma), a fixed-dose combination of the synthetic retinoid adapalene 0.1% and the oxidizing agent benzoyl peroxide 2.5%, is now available over the counter (OTC) for topical treatment of acne in patients ≥12 years old. The gel will remain available by prescription in the same strength for use in patients 9-11 years old. A gel containing adapalene 0.3% and benzoyl peroxide 2.5% (Epiduo Forte, and generics) is available by prescription for use in patients ≥12 years old.
PHARMACOLOGY — Topical retinoids are often used for first-line treatment of acne, either alone or in combination with a topical antibiotic or topical benzoyl peroxide, which also has antibacterial activity. Adapalene modulates keratinization, inflammation, and differentiation of follicular epithelial cells, decreasing formation of comedones and inflammatory lesions. Retinoid/antimicrobial combinations …